According to this new report, the global cardiac biomarkers testing market is estimated to be valued at US$ 5.7 billion in the year 2028, growing at a CAGR of 8.5% in the period 2020 to 2028. Growth of the market is driven by the prevalence of cardiovascular cases, increasing geriatric population, higher precision and its non-invasiveness.
Cardiac biomarkers testing is used for diagnosis of various cardiovascular diseases such as cardiac ischemia, myocardial infarction, congestive heart failure, and acute coronary syndrome. Cardiac Biomarkers are basically protein molecules that are released into the bloodstream after heart damage or heart-stress. Hence measuring biomarkers usually serves as an important early step in diagnosing a heart attack.
The use of cardiac biomarkers in combination are widely applied in clinical diagnosis, risk stratification, and management of patients with or without cardiovascular diseases. One of the potent cardiac biomarker combinations is that of cTn and BNP which is quantitative markers of cardiac damage.
Parameter Description
Segments Covered
The report provides revenue forecasts for global, regional, and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, the publisher has segmented global cardiac biomarkers testing market report on the basis of type, applications, testing location and geography.
Biomarkers Testing Type Outlook
Biomarkers Testing Application Outlook
Biomarkers Testing Location Outlook
Country Outlook, Revenue
Vendors Outlook
Target Audience
